Anthony Jones, PA
Medical · Johnson City, TNNPI 1841814803
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 431 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,801, 5.3 times the $526 reported in 2021. Among medical clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 431 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$1K
- GSK$1K
- CSL Behring$992
- Takeda Pharmaceuticals U.S.A., Inc.$904
- Genentech USA, Inc.$654
- plus $3K from 24 others
What the payments were for
- Food & beverage$9,43798%
- Education$2332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $1,756 |
| Amgen | 74 | $1,330 |
| GSK | 71 | $1,159 |
| CSL Behring | 40 | $992 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $904 |
| Genentech USA, Inc. | 25 | $654 |
| Grifols USA, LLC | 23 | $590 |
| Regeneron Healthcare Solutions, Inc. | 18 | $522 |
| Sanofi | 20 | $508 |
| Kaleo, Inc. | 8 | $163 |
| Novartis | 7 | $142 |
| Galderma Laboratories, L.p. | 3 | $131 |
| Mylan Specialty L.p. | 8 | $115 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $112 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Boehringer Ingelheim | 6 | $95 |
| Biocryst US Sales Co., LLC | 4 | $78 |
| Teva Pharmaceuticals USA, Inc. | 3 | $42 |
| Alk-abello, Inc | 1 | $38 |
| Paratek Pharmaceuticals, Inc. | 1 | $35 |
| Verona Pharma, Inc. | 2 | $33 |
| Ionis Pharmaceuticals, Inc. | 1 | $27 |
| Optinose US, Inc. | 1 | $26 |
| Viatris Specialty LLC | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Pfizer | 1 | $18 |
| Inogen, Inc. | 1 | $18 |
| Greer Laboratories, Inc. | 1 | $17 |
| Hospira, Inc. | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,670 in reported general payments places this provider in the 95th percentile of 480 medical providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 153 | $119,788 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $14,975 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $13,929 |
| Spiriva HandihalerTiotropium Bromide | 20 | $10,251 |
| Epinephrine | 42 | $7,266 |
| Arnuity ElliptaFluticasone Furoate | 28 | $6,721 |
| Qvar RedihalerBeclomethasone Dipropionate | 15 | $4,191 |
| Azelastine Hcl | 126 | $3,965 |
| Fluticasone Propionate | 156 | $2,610 |
| Fluticasone Propionate HfaFluticasone Propionate | 11 | $2,554 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,467 |
| Ipratropium Bromide | 65 | $1,937 |
| Olopatadine Hcl | 14 | $1,723 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $1,340 |
| Montelukast Sodium | 49 | $548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,159 | $141,484208 claims |
| AstraZenecaSymbicort | $1,756 | $13,92960 claims |
| Hikma Pharmaceuticals USAEpinephrine | $19 | $7,26642 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $42 | $4,19115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 480 medical providers in Tennessee.
Other medical in Johnson City
- Meg EllisJohnson City$8K
- Brandon HugginsJohnson City$6K
- Maria WoodChattanooga$130K
- Alyssa JamesonFranklin$65K
- Melissa LambertHendersonville$47K
- Stephanie HowardKnoxville$18K
- Evan HatfillNashville$18K
- Meredith McDanielChattanooga$17K
- Janet BreedingKnoxville$15K
- Paul MabenKnoxville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.